Ticker: INKT

MiNK Therapeutics (NASDAQ: INKT) saw a 200% stock surge after positive clinical trial results for its agenT-797 therapy in metastatic testicular cancer. The treatment led to complete remission in a patient resistant to prior therapies and boasts a favorable safety profile. Investors should watch ...

MiNK Therapeutics, Inc. (NASDAQ: INKT) Overview MiNK Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company has been active in advancing its prop...